EUVIMEDEUVIMED entdecken
Multizentrische Studie

Deferred Cytoreductive Nephrectomy in Unresectable/Metastatic Renal Cell Carcinoma: A Real‐World Multicenter Retrospective Study

Ryuma Tanaka, Masanao Shinohara, Yohei Kawashima, Yuya Sekine, Shintaro Narita, Shin Kobayashi iD, Noriyuki Abe iD, Hirotake Kodama iD, Naoki Fujita iD, Teppei Okamoto, Hayato Yamamoto, Kazuyuki Numakura und 4 weitere

International Journal of Urology · 2026-01 · 33 (1)

DOI: 10.1111/iju.70356 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Urology, online erschienen am 21.01.2026. Verfasst von Ryuma Tanaka und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Nephrectomy, Cytoreduction Surgical Procedures. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: AstraZeneca, Ono Pharmaceutical, Bayer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The role of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC) remains controversial in the era of modern systemic therapy. We aimed to evaluate the proportion of patients undergoing deferred CN (dCN) and their oncological outcomes in a real‐world setting.

Methods

We retrospectively reviewed 651 patients with mRCC who received first‐line tyrosine kinase inhibitors (TKIs) or immune‐oncology (IO) combinations (nivolumab–ipilimumab or IO–TKI) between 2006 and 2025 at 22 Japanese institutions. Patients with prior nephrectomy or follow‐up < 3 months were excluded, leaving 278 eligible patients (TKI 101, IO–TKI 115, Nivo–Ipi 62). Patients were categorized into dCN and non‐nephrectomy groups. Outcomes assessed included the proportion of patients undergoing dCN, disease‐free survival (DFS), overall survival (OS), and perioperative morbidity. Propensity score–matching and multivariable time‐dependent Cox regression were performed.

Results

Among 278 patients, 58 (20.9%) underwent dCN (TKI: 24.8%, IO‐TKI: 15.7%, and Nivo‐Ipi: 24.2%) after a median of 6.6 months of systemic therapy. In the propensity score–matched cohort ( n = 58 per group), dCN was significantly associated with improved survival (DFS: HR 0.38; OS: HR 0.19; both p < 0.001). Perioperative complications occurred in 27.6% (grade ≥ 3 in 3.4%) with no grade 4–5 events. Notably, 34.5% were able to discontinue systemic therapy without recurrence, indicating the possibility of durable treatment‐free disease control in a subset of patients.

Conclusions

Deferred CN (dCN) was feasible and associated with prolonged survival in selected patients with mRCC. Prospective trials are warranted to confirm its role and refine patient selection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsNephrectomyCytoreduction Surgical ProceduresHumansRetrospective StudiesMaleFemaleAgedMiddle AgedJapanTreatment OutcomeProtein Kinase InhibitorsAntineoplastic Combined Chemotherapy ProtocolsDisease-Free Survival

Stichwörter der Autor:innen

cytoreductive nephrectomyimmune‐oncology combination therapyreal‐world studyrenal cell carcinomasurvival outcomes

Substanzen

Protein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
  • Department of Urology, Ageo Central General Hospital, Ageo, Japan.
  • Department of Urology, Akita University Graduate School of Medicine, Akita, Japan.
  • Department of Urology, Asahikawa Medical University, Asahikawa, Japan.
  • Department of Advanced Transplant and Regenerative Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.

ORCID-Profile: Shin Kobayashi, Noriyuki Abe, Hirotake Kodama, Naoki Fujita, Shingo Hatakeyama

Förderung

  • AstraZeneca
  • Ono Pharmaceutical
  • Bayer
  • Pfizer
  • Japan Society for the Promotion of Science
  • Janssen Pharmaceuticals
  • Astellas Pharma
  • Kyorin

Zitieren

APA

Tanaka, R., Shinohara, M., Kawashima, Y., Sekine, Y., Narita, S., Kobayashi, S., Abe, N., Kodama, H., Fujita, N., Okamoto, T., Yamamoto, H., Numakura, K., Sato, S., Habuchi, T., Ohyama, C., & Hatakeyama, S. (2026). Deferred Cytoreductive Nephrectomy in Unresectable/Metastatic Renal Cell Carcinoma: A Real‐World Multicenter Retrospective Study. International Journal of Urology, 33(1). https://doi.org/10.1111/iju.70356

Vancouver

Tanaka R, Shinohara M, Kawashima Y, Sekine Y, Narita S, Kobayashi S, et al. Deferred Cytoreductive Nephrectomy in Unresectable/Metastatic Renal Cell Carcinoma: A Real‐World Multicenter Retrospective Study. International Journal of Urology. 2026;33(1). doi:10.1111/iju.70356

BibTeX
@article{Tanaka2026,
  author = {Tanaka, Ryuma and Shinohara, Masanao and Kawashima, Yohei and Sekine, Yuya and Narita, Shintaro and Kobayashi, Shin and Abe, Noriyuki and Kodama, Hirotake and Fujita, Naoki and Okamoto, Teppei and Yamamoto, Hayato and Numakura, Kazuyuki and Sato, Satoshi and Habuchi, Tomonori and Ohyama, Chikara and Hatakeyama, Shingo},
  title = {Deferred Cytoreductive Nephrectomy in Unresectable/Metastatic Renal Cell Carcinoma: A Real‐World Multicenter Retrospective Study},
  journal = {International Journal of Urology},
  year = {2026},
  volume = {33},
  number = {1},
  doi = {10.1111/iju.70356}
}
Kostenlos starten →